Search Results 771-780 of 17502 for bisphosphonates side effects

1. Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer - Mayo Clinic

   ... side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current ...

2. Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer - Mayo Clinic

   ... side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current ...

3. Medical Research & Education - Mayo Clinic News Network

   ... side. Cancer. Joint study finds proton beam therapy helps patients with throat cancer live longer with fewer side effects. Jessica Saenz. December 11, 2025.

4. ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D - Mayo Clinic

   ... side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current ...

5. A Study to Evaluate Niraparib and TSR-042 in Patients with Germline or Somatic BRCA1/2 and PALB2-related Pancreatic Cancer - Mayo Clinic

   ... side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current ...

6. Muscle pain - Mayo Clinic

   Chemotherapy side effects: A cause of heart disease? Chronic pain: Medication decisions · Claudication · Coconut oil: Can it cure hypothyroidism? Cold and flu ...

7. hyperparathyroidism Archives - Mayo Clinic News Network

   ... side effects. Learn more from Dr. Alaina Softing Hataye, a Mayo Clinic optometrist. Can people with atrial fibrillation participate in physical activity ...

8. Patent foramen ovale - Doctors and departments - Mayo Clinic

   Heart & Blood Health Discussions. mfv · I'm worried about taking statins and side effects. 100 Replies Fri, Feb 20, 2026.

9. First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors - Mayo Clinic

   ... side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current ...

10. Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer - Mayo Clinic

    ... side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current ...